LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported results for the first quarter ended March 31, 2008. Cubist’s net revenues from CUBICIN® (daptomycin for injection) increased 48% from the prior year, from $59.4 million in the first quarter of 2007 to $87.9 million in the first quarter of 2008. U.S. net product revenue for the first quarter of 2008 was $86.1 million. Cubist’s total revenues for the first quarter of 2008 increased 48% over the first quarter of 2007 from $59.5 million in the first quarter of 2007 to $88.3 million in the first quarter of 2008.
